Desmopressin for the treatment of female storage lower urinary tract symptoms

Table 1 Summary of studies investigating desmopressin in female storage

Study	Indication	Design	Desmopressin dose/formulation	Comparator	n	Primary end-point	Result
Lose et al[8], 2003	Nocturia	RCT	0.1, 0.2, 0.4 mg oral, hard tablet	Placebo	144	Percent of patients with > 50% reduction in nocturia	Significant vs placebo
Weiss et al[9], 2012	Nocturia	RCT	10, 25, 50, 100 μg oral lyophylizate	Placebo	341	Reduction in no of voids, patients with > 33% reduction in nocturia	Significant vs placebo for both co-primary end-points
Yamaguchi et al[11], 2013	Nocturia	RCT	10, 25, 50, 100 μg oral lyophylizate	Placebo	58	Reduction in nocturia episodes	Significant vs placebo for 25 and 50 mg
Sand et al[13], 2013	Nocturia	RCT	25 μg oral lyophylizate	Placebo	261	Reduction in nocturia episodes, percent of responders (> 33% reduction)	Significant vs placebo
Hilton et al[14], 1983	Nocturia (MS )	RCT, crossover design	20 μg nasal	Placebo	16	Reduction in nocturia episodes	Significant vs placebo
Eckford et al[15], 1994	Nocturia (MS)	RCT	20 μg nasal	Placebo	22	Reduction in nocturia episodes	Significant vs placebo
Eckford et al[16], 1995	Nocturia (MS)	Open label, non-randomized, placebo controlled, incremental dose	20, 40 , 60 μg nasal	-	8	Nocturnal urinary volume and osmolarities	Significant vs placebo
							No significant for 40 and 60 vs 20 μg
Robinson et al[18], 2004	Daytime incontinence (any type)	RCT, crossover design	40 μg nasal	Placebo	60	4-h post-dose periods with no urine leakage	Significant vs placebo
Hashim et al[19], 2009	OAB	RCT, crossover design	0.2 mg oral, hard tablet	Placebo	41	Time to various OAB symptoms in 8 h post dose	Significant vs placebo
Han et al[20], 2011	OAB	Open label, randomized	Desmopressin 0.2 mg plus solifenacin 5 mg	Desmopressin 0.2 mg	68	Time to first frequency or urgency episode	Significant for combination vs desmopressin monotherapy

RCT: Randomized controlled trial; OAB: Overactive bladder.